These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29033841)

  • 1. Pharmacodynamic Evaluation and PK/PD-Based Dose Prediction of Tulathromycin: A Potential New Indication for
    Zhou YF; Peng HM; Bu MX; Liu YH; Sun J; Liao XP
    Front Pharmacol; 2017; 8():684. PubMed ID: 29033841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic modeling of tylosin against Streptococcus suis in pigs.
    Huang L; Zhang H; Li M; Ahmad I; Wang Y; Yuan Z
    BMC Vet Res; 2018 Oct; 14(1):319. PubMed ID: 30355326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against
    Zhou Q; Zhang G; Wang Q; Liu W; Huang Y; Yu P; Li Y; Ding H; Fang B
    Front Pharmacol; 2017; 8():392. PubMed ID: 28701951
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Guo LL; Gao RY; Wang LH; Lin SJ; Fang BH; Zhao YD
    Front Vet Sci; 2021; 8():715887. PubMed ID: 34869712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation of a rational dosage regimen of ceftiofur hydrochloride oily suspension by pharmacokinetic-pharmacodynamic (PK-PD) model for treatment of swine
    Luo W; Wang D; Qin H; Chen D; Pan Y; Qu W; Huang L; Xie S
    J Vet Sci; 2021 Nov; 22(6):e41. PubMed ID: 34854264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic Target Assessment and PK/PD Cutoff Determination for Gamithromycin Against
    Wang RL; Liu P; Chen XF; Yao X; Liao XP; Liu YH; Sun J; Zhou YF
    Front Vet Sci; 2022; 9():945632. PubMed ID: 35898553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model.
    Zhao Y; Guo LL; Fang B; Liu B
    PLoS One; 2018; 13(12):e0209177. PubMed ID: 30596709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PK-PD Integration Modeling and Cutoff Value of Florfenicol against
    Lei Z; Liu Q; Yang S; Yang B; Khaliq H; Li K; Ahmed S; Sajid A; Zhang B; Chen P; Qiu Y; Cao J; He Q
    Front Pharmacol; 2018; 9():2. PubMed ID: 29387013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standard PK/PD concepts can be applied to determine a dosage regimen for a macrolide: the case of tulathromycin in the calf.
    Toutain PL; Potter T; Pelligand L; Lacroix M; Illambas J; Lees P
    J Vet Pharmacol Ther; 2017 Jan; 40(1):16-27. PubMed ID: 27501187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PK-PD Modeling and Optimal Dosing Regimen of Acetylkitasamycin against
    Huang A; Mao F; Huang L; Xie S; Pan Y; Qu W; Cheng G; Liu Z; Yuan Z; Peng D; Hao H
    Antibiotics (Basel); 2022 Feb; 11(2):. PubMed ID: 35203885
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetic/Pharmacodynamic Relationships of Tulathromycin Against
    Yao L; Yang L; Ling Y; Wei Y; Shen X; Ding H
    Front Vet Sci; 2022; 9():822432. PubMed ID: 35419449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PK-PD Analysis of Marbofloxacin against
    Lei Z; Liu Q; Yang B; Khaliq H; Cao J; He Q
    Front Pharmacol; 2017; 8():856. PubMed ID: 29209222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synovial and Systemic Pharmacokinetics of Florfenicol and PK/PD Integration against
    Somogyi Z; Mag P; Kovács D; Kerek Á; Szabó P; Makrai L; Jerzsele Á
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.
    Lepak AJ; Zhao M; Liu Q; Wang P; Wang Y; Bader JC; Ambrose PG; Andes DR
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility evaluation and PK/PD integration of tulathromycin against
    Wang H; Zhang L
    Front Vet Sci; 2024; 11():1407907. PubMed ID: 39051006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-Pharmacodynamic Modeling of Enrofloxacin Against Escherichia coli in Broilers.
    Sang K; Hao H; Huang L; Wang X; Yuan Z
    Front Vet Sci; 2015; 2():80. PubMed ID: 26779495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.
    Lepak AJ; Andes DR
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis.
    Blondeau JM; Fitch SD
    PLoS One; 2019; 14(1):e0210154. PubMed ID: 30629633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
    Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.